At close: 3:29:13 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,642,101.00
--
1,333,590.00
1,282,267.00
947,393.00
Cost of Revenue
906,014.00
--
737,939.00
748,143.00
514,933.00
Gross Profit
736,087.00
--
595,651.00
534,124.00
432,460.00
Operating Expense
500,765.00
485,201.00
404,483.00
327,745.00
281,214.00
Operating Income
235,322.00
211,541.00
191,168.00
206,379.00
151,246.00
Net Non Operating Interest Income Expense
-68,104.00
-74,907.00
-56,967.00
-29,099.00
-24,785.00
Pretax Income
176,124.00
--
168,761.00
190,079.00
132,327.00
Tax Provision
52,091.00
--
41,175.00
37,654.00
25,502.00
Net Income Common Stockholders
124,033.00
--
127,586.00
152,425.00
106,825.00
Diluted NI Available to Com Stockholders
124,033.00
--
127,586.00
152,425.00
106,825.00
Basic EPS
5.98
5.69
6.86
10.09
708.58
Diluted EPS
5.96
5.69
6.86
10.09
708.58
Basic Average Shares
20,681.26
20,525.00
18,593.00
15,100.00
150.76
Diluted Average Shares
21,749.91
20,525.00
18,593.00
15,100.00
150.76
Total Expenses
1,406,779.00
1,321,976.00
1,142,422.00
1,075,888.00
796,147.00
Net Income from Continuing & Discontinued Operation
124,033.00
--
127,586.00
152,425.00
106,825.00
Normalized Income
121,961.14
114,549.48
128,494.73
151,925.41
106,825.00
Interest Income
--
1,252.00
2,658.00
--
163.00
Interest Expense
60,648.00
67,451.00
54,875.00
25,879.00
1,734.00
Net Interest Income
-68,104.00
-74,907.00
-56,967.00
-29,099.00
-24,785.00
EBIT
236,772.00
226,448.00
223,636.00
215,958.00
134,061.00
EBITDA
431,640.00
406,953.00
373,496.00
312,632.00
214,644.00
Reconciled Cost of Revenue
906,014.00
--
737,939.00
748,143.00
514,933.00
Reconciled Depreciation
194,866.00
--
149,860.00
80,583.00
80,583.00
Net Income from Continuing Operation Net Minority Interest
124,033.00
--
127,586.00
152,425.00
106,825.00
Total Unusual Items Excluding Goodwill
2,942.00
2,942.00
-1,202.00
623.00
--
Total Unusual Items
2,942.00
2,942.00
-1,202.00
623.00
--
Normalized EBITDA
428,698.00
404,011.00
374,698.00
312,009.00
214,644.00
Tax Rate for Calcs
0.00
--
0.00
0.00
0.00
Tax Effect of Unusual Items
870.14
782.48
-293.27
123.41
--
3/31/2021 - 3/16/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BAJAJHCARE.NS Bajaj HealthCare Limited
435.65
-1.18%
MEDICAMEQ.NS Medicamen Biotech Limited
571.55
-1.44%
SOLARA.NS Solara Active Pharma Sciences Limited
746.10
-1.74%
INDSWFTLTD.NS Ind-Swift Limited
29.49
-4.07%
VENUSREM.NS Venus Remedies Limited
340.45
+0.65%
LINCOLN.NS Lincoln Pharmaceuticals Limited
918.85
-2.50%
SEQUENT.NS Sequent Scientific Limited
184.44
-2.53%
SUVENPHAR.NS Suven Pharmaceuticals Limited
1,276.35
-1.57%
SYNCOMF.NS Syncom Formulations (India) Limited
21.74
-3.59%
GRANULES.NS Granules India Limited
589.30
+0.68%